NCT04159688CompletedEarly Phase 1
Imaging Glutamate Release From Alcohol
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Completed
- Sponsor
- Yale University
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Alcohol-induced Change in Receptor Availability
Study Overview
Brief Summary
The goal of this research project is to determine the sensitivity of PET radioligands specific for targets in the glutamate system to an alcohol challenge.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 21 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Men and women, aged 21-55 years
- •Willing and able to give voluntary written informed consent
- •Able to read and write English and communicate effectively with the investigators, and comply with all study requirements, restrictions, and directions of the clinic staff
- •Moderate Drinkers will report consuming alcohol on at least one occasion in the past three months that would result in an estimated blood alcohol level greater than 100 mg/dl but not meet DSM-5 criteria for AUD. This is to ensure that subjects have prior drinking exposure consistent with levels proposed in this study. Prospective subjects will be asked to recall the heaviest two days of drinking in the previous three months. Using this information, approximate BAC will be calculated for those prior episodes.
- •Medically healthy upon physical examination and laboratory testing.
Exclusion Criteria
- •Individuals whom the investigators deem may not be able to comply with alcohol abstinence for 48 hours prior to study day.
- •Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology.
- •History of or current neurological or significant psychiatric disorder such as schizophrenia or bipolar disorder (DSM-5 Axis 1).
- •Other substance use disorder with the exception of nicotine dependence in smokers as assessed with the SCID or positive urine screen for drugs of abuse.
- •Participants with any significant current medical conditions that would contraindicate the consumption of alcohol, such as history of neurological trauma or diseases, seizures, delirium or hallucinations, hepatic, or other unstable medical conditions.
- •Current suicidal or homicidal intent or behavior, or history of suicidal or homicidal behavior.
- •No barbiturates or other known microsomal enzyme induces or inhibitors in the past month.
- •History of significant head trauma.
- •Women who are pregnant or nursing or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD).
- •Regular or current significant use of any prescription, herbal or illegal psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, ecstasy) in the past 6 mo, with no current illegal drug use confirmed by urine toxicology (except for cocaine and marijuana when relevant).
- •Have MRI-incompatible implants and other contraindications for MRI, such as a pacemaker, artificial joints, non-removable body piercings, claustrophobia, etc.
- •Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year.
- •Subjects with current, past or anticipated exposure to radiation in the work place within one year of proposed research PET scans.
- •Subjects with history of IV drug use which would prevent venous access for PET tracer injection.
- •Blood donation within eight weeks of the start of the study
- •History of blooding disorder or currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).
Arms & Interventions
Alcohol Challenge
Experimental
Alcohol Challenge, oral, targeting BAL of 60 mg/dL, Given once
Intervention: Alcohol (Drug)
Outcomes
Primary Outcomes
Alcohol-induced Change in Receptor Availability
Time Frame: Baseline and within 2 hours of challenge
The percent change in receptor availability will be measured from the PET data. Since this project is for basic science it is not known whether positive values are better or worse outcome.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Early Phase 1
Measuring the Neuroimmune Response to AlcoholAlcohol DrinkingNCT04251221Yale University14
Completed
Phase 1
Kappa-PET Imaging and Naltrexone in Alcohol Drinking BehaviorsAlcohol DrinkingNCT01625611Yale University59
Completed
Not Applicable
PET Imaging of mGLuR5 With Drug ChallengePost-Traumatic Stress Disorder (PTSD)Major Depressive DisorderNCT01691092Yale University79
Completed
Phase 1
Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)Breast CancerNCT00968409Washington University School of Medicine20
Completed
Not Applicable
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of AlcoholismAlcoholismNCT00612352Yale University180